Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Publication date
2023-02-16
Authors
Huiberts, Anne
de Gier, Brechje
Hoeve, Christina E
de Melker, Hester E
Hahné, Susan Jm
center, Radboud
van de Wijgert, Janneke H H M
van den Hof, Susan
Knol, Mirjam J
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.
Keywords
COVID-19, SARS-CoV-2, vaccine effectiveness, Public Health, Environmental and Occupational Health, Epidemiology, Virology
Citation
Huiberts, A J, de Gier, B, Hoeve, C E, de Melker, H E, Hahné, S J, center, R, van de Wijgert, J H, van den Hof, S & Knol, M J 2023, 'Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022', Eurosurveillance, vol. 28, no. 7. https://doi.org/10.2807/1560-7917.ES.2023.28.7.2300087